Hope | Jotup

NMDP to Present New Stem Cell Transplantation Data at the 2024 American Society of Clinical Oncology Annual Meeting

Retrieved on:

Wednesday, April 24, 2024

City, NMDP, MMUD, HLA, Haematopoietic system, Hematology, Hope, HCT, Research, Associate professor, ASCO, Bone marrow, Patient, ACCESS, Society, CDT, Medical college, Dentistry

MINNEAPOLIS, April 24, 2024 (GLOBE NEWSWIRE) -- NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®) will present new data on hematopoietic cell transplantation (HCT) treatment effects in patients with hematological malignancies at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31–June 4, 2024, in Chicago, Ill., and online.

Key Points:

MINNEAPOLIS, April 24, 2024 (GLOBE NEWSWIRE) -- NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®) will present new data on hematopoietic cell transplantation (HCT) treatment effects in patients with hematological malignancies at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31–June 4, 2024, in Chicago, Ill., and online.
A chief focus will be sharing interim findings from ACCESS, the prospective, multi-center, Phase II clinical trial of HCT using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children.
“New findings from the ACCESS study will advance broader understanding of how mismatched unrelated donors can safely and effectively address gaps in equitable access to transplant for those patients who are unable to find a fully matched donor,” said Steven M. Devine, M.D., Chief Medical Officer, NMDP; Senior Scientific Director, CIBMTR.
Presenting Author: Monzr M. Al Malki, M.D., Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Title: Identifying states for targeted alloHCT access initiatives using social vulnerability, physician density, and unmet need
Full abstracts will be available at 4 p.m. CDT, May 23, 2024, on the ASCO Annual Meeting website .

Canadians Come Together to Make Positive Impact During Multiple Sclerosis Awareness Month This May

Retrieved on:

Wednesday, April 24, 2024

Volunteering, Social media, Hope, Multiple sclerosis research, Research, Friends, Disease, Family, Caregiver, Parliament, Diagnosis, Multiple sclerosis, DSM-IV codes, Government, Quality of life, Letter, Prevalence, Online shopping

TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- May is Multiple Sclerosis (MS) Awareness Month and MS Canada invites Canadians to join the MS community and navigate MS together.

Key Points:

TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- May is Multiple Sclerosis (MS) Awareness Month and MS Canada invites Canadians to join the MS community and navigate MS together.
MS Awareness Month is an opportunity to raise awareness and funds to support the over 90,000 Canadians living with the neurological disease.
This May we ask Canadians to come together and raise awareness, celebrate the MS community, and have a meaningful impact across Canada.
For more information about MS Awareness Month, including how you can get involved, please visit mscanada.ca/msawarnessmonth.

Regeneration Biomedical Doses First Patient in a First-in-Human Phase I Clinical Trial of Stem Cell Therapy delivered directly into the brain of Patients with Alzheimer’s Disease

Retrieved on:

Tuesday, April 23, 2024

Stem cells have represented a novel approach to treatment, but evidence of efficacy has been elusive because systemically administered cells are unable to bypass the blood brain barrier (BBB) and enter the brain.

Key Points:

Stem cells have represented a novel approach to treatment, but evidence of efficacy has been elusive because systemically administered cells are unable to bypass the blood brain barrier (BBB) and enter the brain.
Our RB-ADSC product candidate is designed to overcome the BBB by delivering potentially efficacious stem cells directly to the brain.
In vivo studies demonstrated that stem cells injected in this fashion do locate into the ventricles and parenchyma.
Research in two animal models has demonstrated that stem cells infused into the ventricular system distribute themselves into brain parenchyma.

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

Retrieved on:

Monday, April 22, 2024

Hope, Hearing loss, Tissue, Regeneron Pharmaceuticals, Gene silencing, Abstract, Gene editing, Cell, Genetics, Senior, Liver, Patient, Gene, Society, Antibody, Clinical trial, Head, Pharmaceutical industry

TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference in Baltimore, Maryland, from May 7 to 11, 2024. Data from 10 abstracts, including six oral presentations, provide insight on Regeneron’s approach to overcoming obstacles to clinical implementation of genetic medicines, from pre-dosing to delivery to long-term sustained expression. The company will also present updated data from the Phase 1/2 CHORD trial investigating DB-OTO in children with profound genetic hearing loss due to mutations of the otoferlin gene.

Key Points:

Data from 10 abstracts, including six oral presentations, provide insight on Regeneron’s approach to overcoming obstacles to clinical implementation of genetic medicines, from pre-dosing to delivery to long-term sustained expression.
The company will also present updated data from the Phase 1/2 CHORD trial investigating DB-OTO in children with profound genetic hearing loss due to mutations of the otoferlin gene.
“Regeneron continues to advance methods to overcome these obstacles through our proprietary delivery approaches utilizing next-generation viral vectors, particularly specific retargeting antibodies and innovative payloads.
The ASGCT presentation will build on promising early results in the first patient,” said Aris Baras, M.D., Senior Vice President, Co-Head of Regeneron Genetic Medicines and Head, Regeneron Genetics Center®.

Excision BioTherapeutics Announces Oral Presentation of Preclinical HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24, 2024

Retrieved on:

Monday, April 22, 2024

CRISPR, Hope, Gene editing, Conference, Research, Patient, Viral, SAN, Vaccine

Excision’s EBT-104 is a CRISPR-based gene therapy that is being developed as a potential cure for HSV-1 Keratitis.

Key Points:

Excision’s EBT-104 is a CRISPR-based gene therapy that is being developed as a potential cure for HSV-1 Keratitis.
EBT-104 utilizes a CRISPR/Cas gene editing system to inactivate the latent HSV-1 virus.
“The exceptional in vivo efficacy demonstrated by our gene editing approach offers new hope for patients suffering from this debilitating condition.
We look forward to sharing these new data from our EBT-104 program at the first CRISPRMED24 Conference.”

Ibogaine By David Dardashti Offers Expanded Treatment Options

Retrieved on:

Sunday, April 21, 2024

Gelastic seizure, Environment, Aftercare, Patient, Dolphin, Swimming, Hope, Growth, Pharmaceutical industry

MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti is proud to announce an expanded treatment program providing greater support and more comprehensive care options to those suffering from addiction.

Key Points:

MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti is proud to announce an expanded treatment program providing greater support and more comprehensive care options to those suffering from addiction.
To ensure every patient receives the best possible treatment, the team at Ibogaine By David Dardashti is now offering a more extensive treatment option.
This includes providing the patient with a free reflection treatment several months after the initial ibogaine treatment to help the person discover the growth that the ibogaine treatment has provided them.
“At Ibogaine By David Dardashti we are committed to providing our patients with the very best care,” said David Dardashti, founder of Ibogaine By David Dardashti.

AGL Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Has Filed a Securities Fraud Class Action Lawsuit Against agilon health, inc. on Their Behalf (AGL)

Retrieved on:

Sunday, April 21, 2024

Lead, LLP, News, Risk, Hope, COPY, Humana, IPO, UnitedHealth Group, District court, Court, Defendant, Medicare, Register, VIEW

RADNOR, Pa., April 21, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ( NYSE: AGL ) (“agilon” or the “Company”).

Key Points:

RADNOR, Pa., April 21, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ( NYSE: AGL ) (“agilon” or the “Company”).
The filing of the Hope Action does not change the May 20, 2024, lead plaintiff deadline.
Kessler Topaz Meltzer & Check, LLP encourages agilon investors who have suffered significant losses to contact the firm directly to acquire more information.
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.

Lt. Gov. Dan Patrick tours $100 million Rio Grande Valley hospital: ‘An answer to prayer’

Retrieved on:

Saturday, April 20, 2024

Brain, Hope, Travel, Robert Coronado, Bed, PHACE syndrome, Heart, Pediatrics, Patient, Physician, Child, Nursing

Dan Patrick visited South Texas on Saturday to tour Driscoll Children’s Hospital Rio Grande Valley.

Key Points:

Dan Patrick visited South Texas on Saturday to tour Driscoll Children’s Hospital Rio Grande Valley.
Dan Patrick said, referring to the long drive patients in the Valley had to make to receive care at Driscoll Children's Hospital Corpus Christi, the nearest specialty acute care hospital for kids.
“The opening of this hospital will be instrumental in improving access to pediatric specialty care for families in the Rio Grande Valley.
Driscoll Children’s Hospital Rio Grande Valley, and the many pediatric subspecialists that will work in it, represent an entirely new level of services previously unavailable close to home,” said Matt Wolthoff, president of Driscoll Children's Hospital Rio Grande Valley.

Journal of Craniofacial Surgery Study Proves Planatome Blades Reduce Tissue Damage and Improve Diabetic Wound Healing from Surgical Incisions

Retrieved on:

Thursday, April 18, 2024

The study highlights the superior performance of Planatome blades in surgical procedures, particularly noting their ability to reduce incisional tissue damage, which reduced inflammation in diabetic rats.

Key Points:

The study highlights the superior performance of Planatome blades in surgical procedures, particularly noting their ability to reduce incisional tissue damage, which reduced inflammation in diabetic rats.
The study found that using ultra-smooth blade technology significantly mitigated tissue injury, which, in turn, lessened inflammation and hasten wound healing.
Scar measurements proved a statistically significant reduction in scar width and scar tissue formation along the incisions made with Planatome blades.
The analysis demonstrated that incisions made using nano-polished Planatome blades resulted in more even, cleaner margins and less damage to surrounding tissue.

Novel cell therapy treatments offer promise to immune-compromised children

Retrieved on:

Thursday, April 18, 2024

Without this therapy, estimates suggest that less than 30% of patients would recover, using standard protocols.

Key Points:

Without this therapy, estimates suggest that less than 30% of patients would recover, using standard protocols.
, the paper’s first author and the Translational Research Laboratory director at the Children’s National Cell Enhancement and Technologies for Immunotherapy (CETI) program.
They combined the expertise at Children’s National in producing and banking cell therapy products with the community built around the PTCTC.
In the decade ahead, Dr. Bollard sees promise in cell therapies for patients with cancer, immune deficiencies after transplant and dozens of other disorders, including genetic and autoimmune diseases.